Milestone Pharmaceuticals (NASDAQ:MIST) Announces Earnings Results

Milestone Pharmaceuticals (NASDAQ:MIST) posted its quarterly earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02, Zacks reports. The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $37.52 million.

Here are the key takeaways from Milestone Pharmaceuticals’ conference call:

• FDA approval of CARDAMYST (etripamil nasal spray) in Dec 2025 and market availability in late January mark the first new PSVT treatment option in ~30 years and the company has begun promotional launch mid‑February.
• Early commercial activity shows encouraging initial traction — retail distribution was established within six weeks, a ~60‑rep sales force is executing >1,000 provider engagements per week, and the company reported >150 prescriptions filled from >100 unique prescribers (mostly new patient starts).
• Milestone reports a strengthened balance sheet with a pro forma cash position of approximately $200 million (including RTW royalty proceeds, ATM sales, and warrant exercises), which management says funds operations into late 2027 to support the launch.
• Payer access is an early headwind — there is no broad contracted coverage yet, and insurer controls (prior authorizations, medical exceptions, quantity limits) are causing delays and dampening prescription fills; management expects commercial coverage in 2026 and Medicare progress more likely in 2027 but timing is uncertain.
• Commercialization spending drove higher expenses and losses in 2025: full‑year commercial expense rose to $28.3M (from $11.0M in 2024) and net loss widened to $63.1 million for the year, indicating near‑term profitability pressure as the launch scales.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.36 on Friday. The business’s fifty day moving average is $1.80 and its 200 day moving average is $1.99. The firm has a market cap of $115.83 million, a price-to-earnings ratio of -1.66 and a beta of 0.48. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06.

Key Headlines Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: FDA approval and commercial launch of CARDAMYST (etripamil) — national sales force deployed, early prescriptions and payer engagement reported; Marketing Authorization Application accepted by the EMA, expanding potential market. These items support longer‑term revenue ramp. Read More.
• Neutral Sentiment: Analyst stance: HC Wainwright keeps a “Buy” rating and an $8 price target, projecting substantial long‑term upside (FY2030 EPS $1.70 in their model). That endorsement supports investor interest but is further out on the timeline. Read More.
• Negative Sentiment: Near‑term analyst revisions: HC Wainwright trimmed FY2028 and FY2029 EPS forecasts (FY28 from $0.53 to $0.45; FY29 from $1.03 to $0.92). The cuts imply a slower initial commercial ramp than previously expected and can pressure the share price. (See MarketBeat coverage above.)
• Negative Sentiment: Financials show widening losses and heavy launch spend — full‑year 2025 net loss of $63.1M and a big increase in commercial expenses as the company scales, raising near‑term cash burn risk despite pro‑forma cash. Continued higher marketing/commercial spend will be a key monitor. Read More.
• Negative Sentiment: Dilution and insider selling: shares outstanding roughly doubled year‑over‑year (issuances, ATM sales and warrant exercises) and multiple insider sales were reported — factors that can amplify downward price pressure. Read More.
• Negative Sentiment: Immediate market reaction: several outlets flagged the stock’s decline today as investors digest mixed news (earnings/launch positives vs. EPS downgrades, losses and dilution). Read More.

Insider Buying and Selling

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00. Following the completion of the transaction, the chief executive officer owned 303,721 shares of the company’s stock, valued at $683,372.25. The trade was a 12.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 113,693 shares of company stock valued at $233,347. 19.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares during the period. Cetera Investment Advisers bought a new stake in Milestone Pharmaceuticals during the 4th quarter worth approximately $42,000. Invesco Ltd. bought a new stake in Milestone Pharmaceuticals during the 4th quarter worth approximately $44,000. Creative Planning lifted its stake in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its stake in Milestone Pharmaceuticals by 30.1% in the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares in the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MIST has been the subject of several research reports. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Zacks Research lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wells Fargo & Company upped their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.